MiMedx Group (MDXG) Resumen de Acciones
MiMedx Group, Inc. desarrolla y distribuye aloinjertos de tejido placentario para diversos sectores de la atención sanitaria. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
MDXG Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de MiMedx Group, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$4.11 |
| Máximo en las últimas 52 semanas | US$7.99 |
| Mínimo de 52 semanas | US$3.03 |
| Beta | 1.45 |
| Cambio en 1 mes | 14.17% |
| Variación en 3 meses | 4.85% |
| Cambio de 1 año | -38.29% |
| Variación en 3 años | -38.75% |
| Variación en 5 años | -62.94% |
| Variación desde la OPV | -19.41% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 02
MDXG: Index Shifts And Guidance Reset Will Present Undervalued Entry Opportunity
MiMedx Group's analyst price targets have been reduced by a combined few dollars across several firms, with the new consensus anchoring to a lower fair value near $5.00 as analysts factor in softer revenue growth expectations, slightly higher profit margins, and updated P/E assumptions. Analyst Commentary Recent Street research on MiMedx Group centers on a series of price target cuts that cluster around the new consensus near US$5.00.
Actualización de narrativa • Jun 18
MDXG: New Wound Care Launches Will Support Chronic Biologics Comeback Narrative
MiMedx Group's consensus analyst price target has been reduced by several dollars to reflect updated assumptions on discount rates, revenue growth, profit margins, and future P/E, with analysts citing recent target cuts from several firms as they refine their outlook on the stock. Analyst Commentary Recent research updates on MiMedx Group point to a more cautious stance on valuation, with several firms trimming price targets by varying dollar amounts.Actualización de narrativa • Jun 04
MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price target on MiMedx Group by a few dollars, citing updated views on profitability and expectations for a higher future P/E multiple as key reasons for the reset. Analyst Commentary Recent Street research has focused on resetting price targets for MiMedx Group by a few dollars at a time, as analysts revisit their assumptions around profitability, execution, and what P/E multiple they are comfortable assigning to the stock.Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking AlphaRecent updates
Actualización de narrativa • Jul 02
MDXG: Index Shifts And Guidance Reset Will Present Undervalued Entry Opportunity
MiMedx Group's analyst price targets have been reduced by a combined few dollars across several firms, with the new consensus anchoring to a lower fair value near $5.00 as analysts factor in softer revenue growth expectations, slightly higher profit margins, and updated P/E assumptions. Analyst Commentary Recent Street research on MiMedx Group centers on a series of price target cuts that cluster around the new consensus near US$5.00.Actualización de narrativa • Jun 18
MDXG: New Wound Care Launches Will Support Chronic Biologics Comeback Narrative
MiMedx Group's consensus analyst price target has been reduced by several dollars to reflect updated assumptions on discount rates, revenue growth, profit margins, and future P/E, with analysts citing recent target cuts from several firms as they refine their outlook on the stock. Analyst Commentary Recent research updates on MiMedx Group point to a more cautious stance on valuation, with several firms trimming price targets by varying dollar amounts.Actualización de narrativa • Jun 04
MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price target on MiMedx Group by a few dollars, citing updated views on profitability and expectations for a higher future P/E multiple as key reasons for the reset. Analyst Commentary Recent Street research has focused on resetting price targets for MiMedx Group by a few dollars at a time, as analysts revisit their assumptions around profitability, execution, and what P/E multiple they are comfortable assigning to the stock.Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking AlphaActualización de narrativa • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Nueva narrativa • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.Nueva narrativa • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Actualización de narrativa • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Actualización de narrativa • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Actualización de narrativa • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Actualización de narrativa • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Actualización de narrativa • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Artículo de análisis • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Artículo de análisis • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Artículo de análisis • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Artículo de análisis • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Artículo de análisis • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Artículo de análisis • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Artículo de análisis • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
Nueva narrativa • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.Rentabilidad de los accionistas
| MDXG | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 4.1% | -2.0% | 0.1% |
| 1Y | -38.3% | 34.9% | 20.3% |
Rentabilidad vs. Industria: Los resultados de MDXG fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 35.8% el año pasado.
Rentabilidad vs. Mercado: MDXG obtuvo unos resultados inferiores a los del mercado US, que fueron del 20.6% el año pasado.
Volatilidad de los precios
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: MDXG no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MDXG (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 808 | Joe Capper | www.mimedx.com |
MiMedx Group, Inc. desarrolla y distribuye aloinjertos de tejido placentario para diversos sectores de la atención sanitaria. La empresa procesa la membrana de los tejidos placentarios humanos, el cordón umbilical y el disco placentario utilizando su proceso PURION patentado y propio para producir aloinjertos que conservan las propiedades biológicas inherentes del tejido y las proteínas reguladoras, incluidas citocinas, quimiocinas y factores de crecimiento. Su método de procesamiento patentado emplea técnicas de procesamiento aséptico además de la esterilización terminal.
Resumen de fundamentos de MiMedx Group, Inc.
| Estadísticas fundamentales de MDXG | |
|---|---|
| Capitalización bursátil | US$612.17m |
| Beneficios(TTM) | US$30.70m |
| Ingresos (TTM) | US$389.42m |
19.9x
Ratio precio-beneficio (PE)1.6x
Ratio precio-ventas (PS)¿Está MDXG sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MDXG | |
|---|---|
| Ingresos | US$389.42m |
| Coste de los ingresos | US$73.82m |
| Beneficio bruto | US$315.59m |
| Otros gastos | US$284.90m |
| Beneficios | US$30.70m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.21 |
| Margen bruto | 81.04% |
| Margen de beneficio neto | 7.88% |
| Ratio deuda/patrimonio | 7.2% |
¿Cómo se ha desempeñado MDXG a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/12 00:48 |
| Precio de las acciones al final del día | 2026/07/10 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
MiMedx Group, Inc. está cubierta por 10 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |